Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, respectively. What's more, obesity alone as an indication bars coverage ...

Tirzepatide is more effective than semaglutide for weight loss, according to a new study on GLP-1 medications ; The study was funded by Eli Lilly, the pharmaceutical company that manufactures ...

The resolution of shortages for tirzepatide and other GLP-1 medications, such as semaglutide, signals a potential shift toward increased FDA enforcement as the agency works to align industry ...

Explore how semaglutide and tirzepatide may protect against dementia and stroke—keep reading for clinical implications and evidence.

How GLP-1 Agonists Might Help With Sleep Apnea. Both semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are GLP-1 agonists, which are medications that help to lower blood sugar ...

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, to a rare eye disease that may cause vision loss.

You may still prescribe compounded GLP-1 drugs, but your prescription must clearly articulate a medically necessary significant difference from the commercially available drug product. Cost ...

A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit, compounded GLP-1 products, warning that consumers may be accessing the… ...